Regeneron Pharmaceuticals (REGN) Current Deferred Revenue (2009 - 2026)

Regeneron Pharmaceuticals' Current Deferred Revenue history runs 18 years deep, the most recent figure standing at $636.2 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue rose 2.73% year-over-year to $636.2 million; the TTM figure through Mar 2026 stood at $636.2 million (up 2.73% YoY), while the FY2025 annual figure was $553.0 million, down 11.9% from the prior year.
• Current Deferred Revenue was $636.2 million for Q1 2026 at Regeneron Pharmaceuticals, up from $553.0 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $636.2 million in Q1 2026 to a low of $381.1 million in Q2 2023.
• Historically, Current Deferred Revenue has averaged $527.1 million across 5 years, with a median of $545.6 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Current Deferred Revenue plunged 32.7% in 2023, then surged 53.77% in 2024.
• A 5-year view of Current Deferred Revenue shows it stood at $477.9 million in 2022, then fell by 3.98% to $458.9 million in 2023, then surged by 36.78% to $627.7 million in 2024, then fell by 11.9% to $553.0 million in 2025, then climbed by 15.05% to $636.2 million in 2026.
• The last three Current Deferred Revenue figures came in at $636.2 million (Q1 2026), $553.0 million (Q4 2025), and $545.6 million (Q3 2025), per Business Quant data.